RxDoctor Payments Data

Eleanor Yip, NP

Acute Care · New York, NYNPI 1407632508

Payments from drug & device makers

$1,459in general payments, 2019–2025

Across 54 payments — averaging $27.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$419
  • Novartis$214
  • Merck$185
  • Pfizer$109
  • Alnylam Pharmaceuticals Inc.$90
  • Scpharmaceuticals Inc.$86
  • plus $356 from 8 others

What the payments were for

  • Food & beverage$1,459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,459 in reported general payments places this provider in the 85th percentile of 980 acute care providers in New York.

See all acute care providers in New York

Medicare billing

Part B allowed, 2024
$2,407
Medicare patients
26
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis54$1,609,151
EntrestoSacubitril/Valsartan167$237,564
EliquisApixaban153$203,057
JardianceEmpagliflozin104$123,981
FarxigaDapagliflozin Propanediol85$95,550
XareltoRivaroxaban28$37,039
BrilintaTicagrelor17$17,319
Eplerenone140$8,458
Metoprolol Succinate212$3,722
Torsemide84$3,126
Amiodarone Hcl24$1,440
Potassium Chloride28$1,272
Atorvastatin Calcium84$1,043
Carvedilol85$799
Losartan Potassium79$736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$109$1,812,208207 claims
NovartisEntresto$214$237,564167 claims
AstraZenecaFarxiga, Brilinta$27$112,869102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 980 acute care providers in New York.

Other acute care in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →